Roger Adsett

Roger Adsett has served as a director of the Company since January 2026. Mr. Adsett has served as Chief Operating Officer of Insmed Inc., a publicly traded biopharmaceutical company focused on treatments for serious and rare diseases (NASDAQ: INSM), since November 2019. Prior to his current position, Mr. Adsett served as Chief Commercial Officer of Insmed from September 2016 until his promotion in November 2019. Mr. Adsett has more than 25 years of experience in the global biotechnology and pharmaceutical industry. From January 2015 to September 2016, Mr. Adsett was Senior Vice President, Head of Gastrointestinal and Internal Medicine Business Unit at Shire. From August 2008 to January 2015, Mr. Adsett was Senior Vice President, Gastrointestinal Business Unit Leader at Shire. From October 2005 to August 2008, Mr. Adsett was General Manager, Oral IBD Products of the Gastroenterology Business Unit of Shire. From November 1994 to October 2005, Mr. Adsett held various marketing and commercial roles at AstraZeneca. Mr. Adsett was a senior analyst at Accenture from September 1991 to November 1994. Mr. Adsett served on the board of Landos Biopharma, Inc. until its acquisition by AbbVie in 2024.

Mr. Adsett holds a Master of Business Administration from The Wharton School at the University of Pennsylvania and a Bachelor of Arts in English and Economics from Bucknell University.